21 completed, 12 recruiting, 8 unknown, 6 terminated. 18 Phase 2, 15 Phase 1, 4 Early Phase 1, 2 Phase 3, 1 Not applicable.
Follow T-Cell Lymphoma: new trials by email Literature Review of T-Cell Lymphoma trials Research Report on T-Cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sample Collection for Ongoing Research and Product Evaluation Study - Non-Hodgkin Lymphoma (SCORE-NHL) Non-Hodgkin Lymphoma, T-Cell Lymphoma | Recruiting | Natera, Inc. | 200 | 2026-07-27 | 2026-08-06 | |
| Epidemiology and Management of Cutaneous T-Cell Lymphoma at Hospital México, Costa Rica. Lymph Node Cancer, Cutaneous | Not yet recruiting | Caja Costarricense de Seguro Social | 350 | 2026-05-01 | 2026-04-20 | |
| Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma azacitidine, abatacept - Lymphoma, T Cell, Peripheral, T-cell Lymphoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 20 | 2026-03-26 | 2026-10-20 |
| Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma Ruxolitinib, Positron emission tomography-computed tomography, Bone Marrow Biopsy - T-cell Lymphoma, Graft Versus Host Disease | Phase 2 | Recruiting | Jonathan Brammer | 44 | 2026-02-12 | 2026-04-15 |
| Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL) Dexamethasone, Vincristine, Daunorubicin - T-cell Acute Lymphoblastic Leukemia, T-cell Lymphoma | Phase 2 | Recruiting | St. Jude Children's Research Hospital | 100 | 2024-12-27 | 2026-08-10 |
| A Study of Enasidenib in People With T-Cell Lymphoma Enasidenib, Rituximab - T-cell Lymphoma | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 2 | 2024-12-24 | 2026-08-20 |
| Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma Mogamulizumab, DA-EPOCH Protocol, CHOEP protocol - T Cell Lymphoma, T-cell Lymphoma | Phase 2 | Recruiting | Yale University | 22 | 2024-10-09 | 2026-04-14 |
| Study of Tazemetostat in Lymphoid Malignancies Tazemetostat - T-cell Lymphoma | Phase 1 | Terminated | University of Alabama at Birmingham | 6 | 2024-09-05 | 2026-04-17 |
| Early Assessment of Lymphoma Treatment Response Using Phased Variant Analysis With Next-Generation Sequencing ctDNA analyzed by phased variant - Lymphoma, Hodgkin Lymphoma | Recruiting | National Taiwan University Hospital | 200 | 2024-08-09 | 2025-06-17 | |
| A Study in Adults With Cutaneous T-cell Lymphoma (CTCL) Retreated With Brentuximab Vedotin No intervention - T-Cell Lymphoma | Completed | Takeda | 26 | 2024-02-08 | 2024-12-04 | |
| Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma Fenretinide - T-cell Lymphoma, Cutaneous/Peripheral T-Cell Lymphoma | Phase 1 | Recruiting | SciTech Development, Inc. | 46 | 2023-12-18 | 2026-10-05 |
| Treatment of Relapsed or Refractory Epstein-Barr Virus Positive T-cell Lymphoma With hNeo-T hNeo-T, Cyclophosphamide, Fludarabine - T-cell Lymphoma | Early Phase 1 | Unknown | BGI, China | 6 | 2023-12-01 | 2024-03-12 |
| Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution 1. Drug: The Venetoclax PK study is collecting bodily fluid samples (ie., whole blood and optional cerebrospinal fluid) of patients prescribed venetoclax as crushed tablets per standard of care. - Hematologic Malignancy, Leukemia | Recruiting | Children's Hospital Medical Center, Cincinnati | 30 | 2023-11-15 | 2026-10-01 | |
| A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies PRT2527, Zanubrutinib, Venetoclax - Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) | Phase 1 | Completed | Prelude Therapeutics Incorporated | 86 | 2023-09-12 | 2026-01-26 |
| A Registry for People With T-cell Lymphoma Optional Blood Sample and Nail Sample - T-cell Lymphoma, NK-Cell Lymphoma | Recruiting | Memorial Sloan Kettering Cancer Center | 1000 | 2023-07-27 | 2026-05-20 | |
| Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma Brentuximab vedotin, Pembrolizumab - T-Cell Lymphoma | Phase 2 | Recruiting | Yale University | 32 | 2023-07-10 | 2026-06-11 |
| A Study of Brentuximab Vedotin Treatment in Chinese Adults With CD30-Positive Cutaneous T-Cell Lymphoma Brentuximab vedotin - T-Cell Lymphoma | Phase 4 | Completed | Takeda | 10 | 2022-11-28 | 2025-09-18 |
| Intravenous Injection of Oncolytic Virus Injection (RT-01) in Patients With Relapsed or Refractory T-cell Lymphoma Oncolytic Virus Injection(RT-01) - T-cell Lymphoma, Virus | Phase 1 | Unknown | The First Affiliated Hospital of Bengbu Medical University | 6 | 2022-05-01 | 2022-05-24 |
| Tucidinostat, Azacitidine Combined With CHOP Versus CHOP in Patients With Untreated Peripheral T-cell Lymphoma Tucidinostat, Azacitidine combined with CHOP - T-cell Lymphoma | Phase 3 | Unknown | Peking Union Medical College Hospital | 107 | 2021-10-01 | 2024-04-09 |
| Study of CD4-Targeted Chimeric Antigen Receptor T-Cells (CD4- CAR-T) in Subjects With Relapsed or Refractory T-Cell Lymphoma LB1901 - T-Cell Lymphoma, Peripheral T-Cell Lymphoma Refractory | Phase 1 | Unknown | Legend Biotech USA Inc | 50 | 2021-09-13 | 2023-10-03 |
Showing 20 of 50. Sign in to see all of them.
Lymphoma, T-Cell (50) · Lymphoma (11) · Lymphoma, Non-Hodgkin (9) · Lymphoma, T-Cell, Cutaneous (8) · Leukemia (6) · Lymphoma, T-Cell, Peripheral (6) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (6) · Recurrence (6) · Leukemia, Lymphocytic, Chronic, B-Cell (5) · Lymphoma, B-Cell (5) · Lymphoma, Large B-Cell, Diffuse (5) · Hodgkin Disease (4) · Immunoblastic Lymphadenopathy (4) · Leukemia, Myeloid, Acute (4) · Lymphoma, Large-Cell, Anaplastic (4)
Hemic and Lymphatic Diseases (50) · Immune System Diseases (50) · Immunoproliferative Disorders (50) · Lymphatic Diseases (50) · Lymphoproliferative Disorders (50) · Neoplasms (50) · Neoplasms by Histologic Type (50) · Lymphoma, Non-Hodgkin (41) · Lymphoma (39) · Hematologic Diseases (19) · Leukemia, Lymphoid (14) · Leukemia (12) · Disease Attributes (10) · Pathologic Processes (10) · Pathological Conditions, Signs and Symptoms (10)
Cyclophosphamide (6) · Brentuximab Vedotin (4) · Methotrexate (4) · Prednisone (4) · Vincristine (4) · Bendamustine Hydrochloride (3) · Doxorubicin (3) · fludarabine (3) · pembrolizumab (3) · Cytarabine (2) · Dexamethasone (2) · Etoposide (2) · Hydrocortisone (2) · Lenalidomide (2) · Rituximab (2)
Memorial Sloan Kettering Cancer Center (3) · National Cancer Institute (NCI) (2) · Takeda (2) · Yale University (2) · AHS Cancer Control Alberta (1) · BGI, China (1) · BioInvent International AB (1) · Caja Costarricense de Seguro Social (1) · Children's Hospital Medical Center, Cincinnati (1) · Children's Oncology Group (1) · Corvus Pharmaceuticals, Inc. (1) · Dana-Farber Cancer Institute (1) · Deepa Jagadeesh (1) · Eli Lilly and Company (1) · Emergent BioSolutions (1)
United States (32) · France (6) · China (5) · Australia (4) · Italy (4) · Canada (3) · Germany (3) · South Korea (3) · Spain (3) · United Kingdom (3) · Denmark (2) · Hungary (2) · Poland (2) · Taiwan (2) · Belgium (1)
Tarsheen Sethi, MD (2) · Aaron R Mangold, M.D. (1) · Ai Wei, M.D. (1) · Ali Moiin, MD (1) · Amanda Cashen, M.D. (1) · Andres McAllister, PhD (1) · Anita Kumar, MD (1) · Ann F Mohrbacher, MD (1) · Auris O Huen, MD, PharmD (1) · Barbara Pro, MD (1) · Brad Haverkos, M.D. (1) · Brian Hill, MD, PhD (1) · Carla Casulo, MD (1)
PMID 1244564, PMID 19597183, PMID 21270441, PMID 21576639, PMID 23109692, PMID 23674495, PMID 23716537, PMID 23770158, PMID 23818604, PMID 24652992, PMID 25113753, PMID 25135998, PMID 25355245, PMID 26009261, PMID 26542718, PMID 27574190, PMID 28188133, PMID 28570279, PMID 28600132, PMID 28974506, PMID 29143824, PMID 29293620, PMID 29669753, PMID 29720488, PMID 30522922, PMID 31029646, PMID 31170847, PMID 33496747, PMID 35470385, PMID 37553297, PMID 40750774, PMID 40829107, PMID 41619724, PMID 42640855, PMID 7165009
2023 (1)